Current Medical Research and Opinion

Prevalence of atherosclerotic vascular disease among subjects with the metabolic syndrome with or without diabetes mellitus: the METS-GREECE Multicentre Study
pp. 1691-1701(11)
Authors: Vasilios G. Athyros; Dimitri P. Mikhailidis; Athanasios A. Papageorgiou; Triandafillos P. Didangelos; Emmanuel S. Ganotakis; Athanasios N. Symeonidis; Stella S. Daskalopoulou; Anna I. Kakafika; Moses Elisaf; Mets-Greece Collaborative Group

The impact of insulin glargine on clinical and humanistic outcomes in patients uncontrolled on other insulin and oral agents: an office-based naturalistic study
pp. 1703-1710(8)
Authors: Jerome S. Fischer; Trent McLaughlin; Litza Loza; Rebecca Beauchamp; Sherwyn Schwartz; Mark Kipnes

Combination therapy in asthma – fixed or variable dosing in different patients?
pp. 1711-1727(17)
Authors: Jan Lötvall

Cost-effectiveness of detemir-based basal/bolus therapy versus NPH-based basal/bolus therapy for type 1 diabetes in a UK setting: an economic analysis based on meta-analysis results of four clinical trials
pp. 1729-1746(18)
Authors: Andrew J. Palmer; Stéphane Roze; William J. Valentine; Inger Smith; Kim U. Wittrup-Jensen

An open-label, comparative study of rivastigmine, donepezil and galantamine in a real-world setting
pp. 1747-1752(6)
Authors: E. Aguglia; M.L. Onor; M. Saina; E. Maso

A comparison of the fourth-generation fluoroquinolones gatifloxacin 0.3% and moxifloxacin 0.5% in terms of ocular tolerability
pp. 1753-1758(6)
Authors: Eric Donnenfeld; Henry D. Perry; Daniel A. Chruscicki; Adam Bitterman; Stephanie Cohn; Renée Solomon

Effects of tirofiban on acute systemic inflammatory response in elective percutaneous coronary interventions
pp. 1759-1767(9)
Authors: Mehmet Akbulut; Yilmaz Ozbay; Ozlem Gundogdu; Necati Dagl; Polat Durukan; Erdogan Ilkay; Nadi Arslan

How to improve current therapeutic standards in upper respiratory infections: value of fusafungine
pp. 1769-1776(8)
Authors: Michèle German-Fattal; Ralph Mösges

Migraine treatment strategies: the global Migraine And Zolmitriptan Evaluation (MAZE) survey – phase IV
pp. 1777-1783(7)
Authors: E. Anne MacGregor; Jan Brandes; Astrid Gendolla; Rose Giammarco

Diagnosing restless legs syndrome (RLS) in primary care
pp. 1785-1795(11)
Authors: K. Ray Chaudhuri; Alison Forbes; Donald Grosset; Andrew Lees; John Shneerson; Anthony Schapira; Paul Stillman; Adrian Williams

The role of angiotensin antagonism in stroke prevention in patients with hypertension: focus on losartan
pp. 1797-1804(8)
Author: Carlos M. Ferrario

The impact of a worksite migraine intervention program on work productivity, productivity costs, and non-workplace impairment among Spanish postal service employees from an employer perspective
pp. 1805-1814(10)
Authors: Teofila Vicente-Herrero; Thomas A. Burke; Miguel J.A. Laínez

Effects of galantamine in patients with mild Alzheimer's disease
pp. 1815-1820(6)
Authors: J-M. Orgogozo; G.W. Small; G. Hammond; B Van Baelen; S. Schwalen

Comment on Putting evidence-based medicine into clinical practice: comparing anti-resorptive agents for the treatment of osteoporosis and Author's Reply
pp. 1821-1824(4)
Authors: Hans-Peter Kruse; Johann D. Ringe; Johannes Pfeilschifter; Dieter Felsenberg; Lois E. Wehren; David Hosking; Marc C. Hochberg

The validity and reliability of the global index of safety (GIS)
pp. 1825-1832(8)
Authors: L. Prieto; J.A. Sacristán; J.C. Gómez

Clopidogrel and vascular disease prevention
pp. 1835-1838(4)
Authors: Stella S. Daskalopoulou; Gerard Stansby; Dimitri P. Mikhailidis

Role of antiplatelet therapy in cardiovascular disease I: acute coronary syndromes
pp. 1839-1843(5)
Authors: Jeffrey J. Cavendish; Randolph V. Fugit; Michael Safani

Role of antiplatelet therapy in cardiovascular disease II: Ischemic stroke
pp. 1845-1849(5)
Authors: Jeffrey J. Cavendish; Steven C. Cramer; Glenn D. Graham

Role of antiplatelet therapy in cardiovascular disease III: Peripheral arterial disease
pp. 1851-1855(5)
Authors: Jeffrey J. Cavendish; Michael Safani